Recruiting

White Button MushroomEffects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer

Sponsor:

City of Hope Medical Center

Code:

NCT04913064

Conditions

Breast Carcinoma

Eligibility Criteria

Sex: Female

Age: 21+

Healthy Volunteers: Accepted

Interventions

Questionnaire Administration

White Button Mushroom Extract

Study Details

Brief summary:

This clinical trial studies the effects of dietary white button mushroom on inflammation (the body's process of fighting against harmful things) and immune cells (white blood cells) in postmenopausal women with both high body mass index or BMI (percentage of body fat) and high risk of breast cancer. The body is in a constant state of alert when inflammation lingers at a low level and becomes chronic, as with having button mushroom is a dietary supplement that may improving responses of immune cells (white blood cells) and decreasing chronic inflammation.

Information gathered from this study may help researchers determine whether white button mushroom have any effects on body fat and breast cancer risk.

Conditions

Breast Carcinoma

Study ID

NCT04913064

Start date

Jul 27, 2021

Status verified date

Dec, 2025

Completion date

Jan 12, 2027

Anticipated

Primary completion date

Jan 12, 2027

Anticipated

Eligibility Criteria

Sex: Female

Age: 21+

Healthy Volunteers: Accepted

Inclusion Criteria:

This study will be conducted in postmenopausal women who have increased risk of breast cancer and high BMI >= 30 kg/m\^2
The study population will consist of women with a relative risk of developing breast cancer that is at least > 2 x that of the general population for their age group based on any of the following:

Have a known genetic mutation associated with hereditary breast cancer (including BRCA1, BRCA2, p53, etc.)
One or more first degree relatives with breast cancer, with at least one under the age of 60
Two or more second degree relatives with breast cancer, with at least one under the age of 50
Prior biopsy diagnosing atypical lobular hyperplasia, atypical ductal hyperplasia, lobular carcinoma in situ, or ductal carcinoma in situ in the last 10 years
Have a Gail Risk Assessment (which is based on age, race, age of menarche, age of first live birth, number of first degree relatives with breast cancer, number of breast biopsies, and presence of high risk histology on any biopsies) that is considered high risk compared to the general population i.e. 5 year Gail >= 1.7
Prior diagnosis of T1 or T2 breast cancer >= 5 years, without antiestrogen therapy for > six months when applicable
ELIGIBILITY CRITERIA FOR HIGH RISK PATIENTS FOR THE CLINICAL TRIAL
Body mass index (BMI) >= 30 (Asian BMI >= 25 kg/m\^2)
Postmenopausal, defined as continuous absence of menstruation for 12+ months, status post bilateral oophorectomy, or status post hysterectomy with follicle stimulating hormone (FSH) in menopausal range
Bilateral mammogram within the 12 months prior to study enrollment that is read as not suspicious for breast cancer (American College of Radiology \[ACR\] class I-III). Subjects with a class IV mammogram may be entered once they have had a negative biopsy. In cases of bilateral mastectomy, documentation that the patient has been continuously without evidence of disease for 5 years will suffice
Serum creatinine of 1.5 X upper limit of institutional norm or less
Total bilirubin of 1.5 X upper limit of institutional norm or less
ALT and aspartate aminotransferase (AST) of less than 2 X upper limit of institutional norm or less
Hemoglobin of 9.0 gm/dL or more
Platelets of 100,000/mm\^3 or more
Total white blood cell (WBC) of 3500/mm\^3
Absolute neutrophil count (ANC) of 1500/mm\^3 or more
Must be willing to have about 40-50 ml of blood (approximately 8-10 teaspoons) drawn at 0 and 3 months
Must be able to swallow pills
This study will assess WBM powder in postmenopausal women of 21 years of age or older. Younger women are unlikely to be postmenopausal
Participants will have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
The effects of WBM on the developing fetus are unknown. Pregnant and women with childbearing potential are not eligible to participate in this study of postmenopausal women at high risk of breast cancer
All subjects must have the ability to understand and the willingness to sign a written informed consent. Participants must be aware of their increased breast cancer risk and willingly consent after being informed of the investigational nature of the intervention, alternatives, potential benefits, side-effects, risks, and discomforts
Prior therapies, including chemoprevention or adjuvant therapies, must have been completed for 6 or more months prior to study entry. Prior use of mushroom or mushroom chemical-containing supplements must have been completed within 3 months of study entry

Exclusion Criteria:

Active malignancy within the past 5 years with the exception of non-melanoma skin cancer or carcinoma in situ of the cervix. NOTE: If there is a history of prior malignancy, the participant must not be receiving other specific treatment, i.e., other hormonal therapy, for their cancer
Ongoing chemotherapy, radiation therapy, or other cancer-related treatment
History of a bleeding tendency or current use of Coumadin or other anticoagulants
Concurrent use of hormone-modifying medications including systemic hormone replacement therapy (local vaginal preparations are permitted), selective estrogen receptor modifiers (SERMs), aromatase inhibitors (Ais), or gonadotropic-releasing hormone (GnRH) modifiers within 3 months of randomization
Concurrent use of immunosuppressant medications
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, hypertension, or psychiatric illness/social situation that would limit compliance with study requirements
Chronic use of any herbal or dietary supplement containing mushrooms within the 3 months prior to entry on the study
Treatment with other investigational agents
Premenopausal status
Known sensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to WBM or
Subjects on a standing regimen of full dose aspirin (>= 325 mg/day), nonsteroidal anti-inflammatory drugs (NSAIDs) or NSAID-containing products
Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

Study Design

Enrollment

26 participants

Anticipated

Intervention Model

Single group

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: Prevention (white button mushroom)

Participants receive white button mushroom PO daily for 3 months in the absence of disease progression or unacceptable toxicity.

Interventions

Questionnaire Administration

Ancillary studies

White Button Mushroom Extract

Given PO

Primary outcome measure

Relative change in levels of circulating myeloid-derived suppressor cells (MDSCs) within the peripheral blood mononuclear (PBMC) compartment [ Time Frame: Baseline up to 3 months ]
Relative change in immune cell composition within the peripheral blood mononuclear (PBMC) compartment [ Time Frame: Baseline up to 3 months ]

Central Contacts and Locations

Locations

City of Hope Medical Center

Recruiting

Duarte, California, United States, 91010

Contacts

Lisa D. Yee

626-471-7100 lyee@coh.org

Principal Investigator:

Lisa D. Yee

More Information

Sponsor

City of Hope Medical Center

Last update posted

Jan 5, 2026

Last verified

Dec, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by City of Hope Medical Center on 2026-01-05.